RNA/DNA Polymerase

MK3281 is a non-nucleoside inhibitor targeting the hepatitis C virus (HCV) NS5B polymerase. It demonstrates significant antiviral activity, with an EC50 of 28 nM for genotype 1a. This compound is utilized in research focused on antiviral drug development and understanding HCV replication mechanisms.

PSI-353661 is a purine nucleotide inhibitor targeting the NS5B polymerase of Hepatitis C Virus (HCV). It demonstrates potent antiviral activity with EC90 values of 8 nM for wild-type HCV and 11 nM for the S282T resistant strain. Additionally, PSI-353661 achieves elevated levels of its active triphosphate form in primary human hepatocytes, making it a valuable tool for studying HCV replication and resistance mechanisms.

HCV NS5B polymerase-IN-3 is a potent inhibitor of the hepatitis C virus (HCV) NS5B polymerase, demonstrating significant antiviral activity. In the Huh7 replicon cell line, it exhibits an EC50 value of 0.23 μM while maintaining a favorable cytotoxicity profile. This compound is relevant for research applications focused on HCV replication and drug development strategies targeting hepatitis C.

VCH-916 free base is a non-nucleoside inhibitor targeting the NS5B polymerase of Hepatitis C virus (HCV). This compound demonstrates potent antiviral activity, making it a valuable tool for research on HCV replication. It is primarily utilized in studies focused on developing effective treatments for Hepatitis C and understanding the viral mechanisms of polymerase function.

GAP-1173149 is a selective inhibitor of the Chikungunya virus (CHIKV) polymerase, specifically targeting the nsP4 RNA-dependent RNA polymerase. This compound demonstrates potent antiviral activity by hindering viral RNA replication, making it a valuable tool for studying CHIKV biology and developing antiviral strategies. Its application is particularly relevant in research focused on emerging viral threats and potential therapeutic interventions for Chikungunya virus infections.

Cidofovir diphosphate is a potent inhibitor of viral DNA polymerases, primarily targeting human cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV-1), and herpes simplex virus type 2 (HSV-2). With Ki values of 6.6 μM, 0.86 μM, and 1.4 μM for these polymers, respectively, it demonstrates selective antiviral activity. This compound is instrumental in research focusing on antiviral drug development and elucidating the mechanisms underlying viral DNA replication.

T-1105 is a novel broad-spectrum viral polymerase inhibitor that acts by being converted into a ribonucleoside triphosphate (RTP) metabolite. This compound demonstrates antiviral activity against multiple RNA viruses by inhibiting their polymerases. T-1105 is particularly significant in studies aimed at understanding viral replication and developing antiviral strategies. Its mechanism of action highlights its potential applications in viral pathogenesis research and therapeutic interventions.